Journal
ANTI-CANCER DRUGS
Volume 15, Issue 10, Pages 955-960Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001813-200411000-00004
Keywords
apoptosis; chemotherapy; multiple myeloma; peroxisome proliferator-activated receptor; PPAR-gamma
Categories
Ask authors/readers for more resources
The activation of proliferator-activated receptor gamma (PPAR-y) by its natural and synthetic ligands induces apoptosis in several tumor cell lines, including malignant B-lineage cells. We investigated whether treatment with pioglitazone (PGZ), rosiglitazone (RGZ) or 15-deoxy-Delta(12,14-) prostaglandin J(2) (15d-PGJ(2)) inhibited tumor cell growth in five human multiple myeloma cell lines (LP-1, U-266, RPMI-8226-S, OPM-2 and IM-9) and human bone marrow myeloma cells expressing PPAR-gamma protein. MTT assays revealed growth arrest induced by the natural activator of PPAR-gamma 15d-PGJ(2) and a lower anti proliferative effect with thiazolidinediones (PGZ and RGZ) in a dose-dependent manner. Induction of apoptosis was indicated by Annexin-V staining. At a dose of 50 muM, 15d-PGJ(2) led to a high rate of apoptosis in all cell lines (60-92%). Furthermore, induction of apoptosis in sorted bone marrow plasma cells from myeloma patients was detected. Thiazolidinediones comprise anti-myeloma activity in vitro and should be explored further for the treatment of multiple myeloma. (C) 2004 Lippincott Williams Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available